+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effect of Cysteamine Injection on Vasopressin and Oxytocin Biosynthesis in Rat Hypothalamus

      , ,


      S. Karger AG

      Cysteamine, Vasopressin, Oxytocin, Biosynthesis, Hypothalamus, Rat

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Cysteamine (CSH), a sulfhydryl agent that promotes disulfide-exchange reactions, was studied for its effects on the immunoreactive (IR) levels and synthesis of oxytocin and vasopressin in the hypothalamus. CSH injection (300 mg/ kg s.c.) caused a rapid (1 h) suppression of <sup>35</sup>S-cysteine incorporation into hypothalamic arginine vasopressin (VP) and oxytocin (OT). The reduction in labeling persisted for about 8 h; label incorporation was normal within 10 h of CSH administration. The drug did not influence <sup>35</sup>S-cysteine incorporation into acid-precipitable protein, nor did it influence <sup>35</sup>S-cysteine specific activity in the hypothalamus. In addition, <sup>35</sup>S-VP and <sup>35</sup>S-OT molecules could not be recovered from hypothalami of CSH-treated rats by subjecting samples to denaturing, reducing and then reoxidizing conditions. Despite the reduction in peptide labeling, CSH treatment produced no alterations in the IR VP and OT contents of hypothalamus or posterior pituitary. These results indicate that CSH causes a true suppression of both VP and OT formation in hypothalamus, and suggest that the effect is either too transient to promote a reduction in endogenous stores of either peptide, or that the drug equally inhibits peptide production and removal (i.e., axonal transport, secretion).

          Related collections

          Author and article information

          S. Karger AG
          08 April 2008
          : 59
          : 3
          : 218-227
          Neuroendocrine Program, Departments of Psychiatry and Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, Pa., USA
          126662 Neuroendocrinology 1994;59:218–227
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 10
          Regulation of Hypothalamic Neurons


          Comment on this article